phospho jak2 tyr1007 1008 Search Results


jak2 antibodies  (Biorbyt)
92
Biorbyt jak2 antibodies
Fig. 2. Baricitinib and tofacitinib similarly inhibit eosinophil differentiation and JAK1/2 activation. Bone marrow cells were collected from the femurs and tibiae of three female BALB/c mice and cultured at 106/mL in media supplemented with 100 ng/mL SCF and 100 ng/mL FLT3L from day 0 to day 4. On day 4, media were replaced with media containing 10 ng/mL IL-5 supplemented with or without baricitinib (BARI, 200 nM) or tofacitinib (TOFA, 200 nM). (A) Total cells, (B) Siglec F positive cells and (C) CCR3 positive cells were enumerated by flow cytometry on the indicated days. On day 12 (D) JAK1 and (E) <t>JAK2</t> phosphorylation was measured by flow cytometric intracellular staining. Data are shown as mean ± SEM from 3 independent experiments, ** P < 0.01, *** P < 0.005; (A-C) two-way ANOVA and (D and E) one- way ANOVA.
Jak2 Antibodies, supplied by Biorbyt, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phospho+jak2+tyr1007+1008/pm34274356-99-20-23?v=Biorbyt
Average 92 stars, based on 1 article reviews
jak2 antibodies - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
anti-jak2 antibody (phospho-tyr 1007/1008) (oaai00696)  (Aviva Systems)
N/A
The Janus tyrosine kinase family is consists of four members, JAK1, JAK2, JAK3 and Tyk2. Upon the cytokine ligand binding to its the receptors, the dimerization of the receptors occurs followed by phosphorylation of the
   Buy from Supplier
anti-phospho-jak2 (tyr1007, 1008) polyclonal antibody  (TargetMol)
N/A
   Buy from Supplier
phospho-jak2 (tyr1007/1008) antibody  (Cell Signaling Technology Inc)
N/A
Members of the Janus family of tyrosine kinases (Jak1, Jak2, Jak3, and Tyk2) are activated by ligands binding to a number of associated cytokine receptors (1). Upon cytokine receptor activation, Jak proteins become autophosphorylated and
   Buy from Supplier
jak2 (phospho-tyr1007/1008) antibody  (biorbyt)
N/A
Rabbit polyclonal to JAK2 (phospho-Tyr1007/1008) Isotype Note: IgG Host Note: Rabbit Conjugation Note: Unconjugated Reactivity Note: Human, Mouse, Rat Application Note: WB, IHC-P, P-ELISA
   Buy from Supplier
anti-phospho-jak2 (tyr1007, 1008) antibody  (TargetMol)
N/A
   Buy from Supplier
fastscan phospho-jak2 (tyr1007/1008) elisa kit  (Cell Signaling Technology Inc)
N/A
Members of the Janus family of tyrosine kinases (Jak1, Jak2, Jak3, and Tyk2) are activated by ligands binding to a number of associated cytokine receptors (1). Upon cytokine receptor activation, Jak proteins become autophosphorylated and
   Buy from Supplier
phospho-jak2 (tyr1007/1008) rabbit mab  (Cell Signaling Technology Inc)
N/A
Members of the Janus family of tyrosine kinases (Jak1, Jak2, Jak3, and Tyk2) are activated by ligands binding to a number of associated cytokine receptors (1). Upon cytokine receptor activation, Jak proteins become autophosphorylated and
   Buy from Supplier
phospho-jak1 (tyr1034/1035)/jak2 (tyr1007/1008) mouse mab  (Cell Signaling Technology Inc)
N/A
Members of the Janus family of tyrosine kinases (Jak1, Jak2, Jak3, and Tyk2) are activated by ligands binding to a number of associated cytokine receptors (1). Upon cytokine receptor activation, Jak proteins become autophosphorylated and
   Buy from Supplier

Image Search Results


Fig. 2. Baricitinib and tofacitinib similarly inhibit eosinophil differentiation and JAK1/2 activation. Bone marrow cells were collected from the femurs and tibiae of three female BALB/c mice and cultured at 106/mL in media supplemented with 100 ng/mL SCF and 100 ng/mL FLT3L from day 0 to day 4. On day 4, media were replaced with media containing 10 ng/mL IL-5 supplemented with or without baricitinib (BARI, 200 nM) or tofacitinib (TOFA, 200 nM). (A) Total cells, (B) Siglec F positive cells and (C) CCR3 positive cells were enumerated by flow cytometry on the indicated days. On day 12 (D) JAK1 and (E) JAK2 phosphorylation was measured by flow cytometric intracellular staining. Data are shown as mean ± SEM from 3 independent experiments, ** P < 0.01, *** P < 0.005; (A-C) two-way ANOVA and (D and E) one- way ANOVA.

Journal: Biochemical pharmacology

Article Title: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.

doi: 10.1016/j.bcp.2021.114690

Figure Lengend Snippet: Fig. 2. Baricitinib and tofacitinib similarly inhibit eosinophil differentiation and JAK1/2 activation. Bone marrow cells were collected from the femurs and tibiae of three female BALB/c mice and cultured at 106/mL in media supplemented with 100 ng/mL SCF and 100 ng/mL FLT3L from day 0 to day 4. On day 4, media were replaced with media containing 10 ng/mL IL-5 supplemented with or without baricitinib (BARI, 200 nM) or tofacitinib (TOFA, 200 nM). (A) Total cells, (B) Siglec F positive cells and (C) CCR3 positive cells were enumerated by flow cytometry on the indicated days. On day 12 (D) JAK1 and (E) JAK2 phosphorylation was measured by flow cytometric intracellular staining. Data are shown as mean ± SEM from 3 independent experiments, ** P < 0.01, *** P < 0.005; (A-C) two-way ANOVA and (D and E) one- way ANOVA.

Article Snippet: On day 12, cells were processed with Fix & Perm (Nordic MUbio) and additionally stained with FITC anti-mouse phospho-JAK1 and JAK2 antibodies (both Biorbyt), evaluated by flow cytometry (BD FACSCanto II) and and analyzed by FlowJo 10.7.1 software.

Techniques: Activation Assay, Cell Culture, Flow Cytometry, Phospho-proteomics, Staining